Nutex Health Faces Delisting Notice

TL;DR

NUTX got a delisting notice, might be moving exchanges or facing compliance issues.

AI Summary

Nutex Health, Inc. filed an 8-K on May 21, 2024, to report a notice of delisting or failure to satisfy a continued listing rule. The company is transferring its listing, indicating a potential change in its stock exchange or compliance status.

Why It Matters

This filing signals potential issues with Nutex Health's compliance with stock exchange listing requirements, which could impact its stock's tradability and investor confidence.

Risk Assessment

Risk Level: high — A notice of delisting or failure to meet listing standards indicates significant compliance issues that could lead to the stock being removed from its current exchange.

Key Numbers

• 001-41346 — Commission File Number (SEC filing identifier for Nutex Health, Inc.)
• 11-3363609 — I.R.S. Employer Identification Number (Tax identification number for Nutex Health, Inc.)

Key Players & Entities

• Nutex Health, Inc. (company) — Registrant
• May 21, 2024 (date) — Date of earliest event reported
• Delaware (jurisdiction) — State of Incorporation
• Houston, Texas (location) — Principal executive offices
• Clinigence Holdings, Inc. (company) — Former company name
• iGambit, Inc. (company) — Former company name

FAQ

Key Financial Figures

• $0.001 — ange on which registered Common Stock, $0.001 par value NUTX The NASDAQ Stock Mar
• $1.00 — on Stock") had closed below the minimum $1.00 per share requirement for continued lis

Filing Documents

• nutx-20240521x8k.htm (8-K) — 30KB
• 0001479681-24-000005.txt ( ) — 184KB
• nutx-20240521.xsd (EX-101.SCH) — 4KB
• nutx-20240521_def.xml (EX-101.DEF) — 3KB
• nutx-20240521_lab.xml (EX-101.LAB) — 12KB
• nutx-20240521_pre.xml (EX-101.PRE) — 12KB
• nutx-20240521x8k_htm.xml (XML) — 5KB

01 Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing

Item 3.01 Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing. As previously disclosed, on May 22, 2023, Nutex Health Inc. (the "Company") received a letter (the "First Nasdaq Bid Price Letter") from The Nasdaq Stock Market LLC ("Nasdaq") indicating that, for thirty consecutive business days prior to the date of such letter, the bid price for the Company's common stock (the "Common Stock") had closed below the minimum $1.00 per share requirement for continued listing on The Nasdaq Capital Market under Nasdaq Listing Rule 5550(a)(2) (the "Minimum Bid Price Requirement"). Subsequently, on November 21, 2023, the Company was provided an additional 180 calendar day period, or until May 20, 2024, to regain compliance (the "Second Compliance Period"). On May 21, 2024, the Company received a letter from the Staff stating that the Company has not regained compliance with the Minimum Bid Price Requirement for The Nasdaq Capital Market. The Staff letter noted that unless the Company timely requests an appeal of this determination to the Nasdaq Hearings Panel (the "Panel") by May 28, 2024, the Company's common stock will be suspended at the opening of business on May 30, 2024, and a Form 25-NSE will be filed with the Securities and Exchange Commission (the "SEC"), which will remove the Company's securities from listing and registration on The Nasdaq Stock Market. On May 23, 2024, the Company submitted a request for a hearing to appeal the Staff's delisting determination. Also on May 23, 2024, Nasdaq notified the Company that the delisting action has been stayed, pending a final decision by the Panel. A hearing has been scheduled for July 9, 2024. The Company intends to provide its written submission by the expedited review deadline of May 30, 2024. Based on such submission, the Panel may determine that an oral hearing is not necessary to grant the Company an exemption to gain compliance with the Minimum Bid Price Requirement.

Forward-Looking Statements

Forward-Looking Statements Certain statements and information included in this current report constitute "forward-looking statements" within the meaning of the Private Securities Litigation Act of 1995. When used in this current report, the words or phrases "will", "will likely result," "expected to," "will continue," "anticipated," "estimate," "projected," "intend," "goal," or similar expressions are intended to identify "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements are subject to certain risks, known and unknown, and uncertainties, many of which are beyond the control of the Company. Such uncertainties and risks include, but are not limited to, our ability to successfully execute our growth strategy, changes in laws or regulations, including final rules implemented under the No Surprises Act and related regulatory guidance, economic conditions, dependence on management, dilution to stockholders, lack of capital, the effects of rapid growth upon the Company and the ability of management to effectively respond to the growth and demand for products and services of the Company, newly developing technologies, the Company's ability to compete, conflicts of interest in related party transactions, regulatory matters, protection of technology, lack of industry standards, the effects of competition and the ability of the Company to obtain future financing. An extensive list of factors that can affect future results are discussed in the Company's Annual Report on form 10-K for the year ended December 31, 2023 and its Current Report on Form 10-Q for the periods ended March 31, 2024, under the heading "Risk Factors" in Part I, Item IA thereof, and other documents filed from time to time with the Securities and Exchange Commission. Such factors could materially adversely affect the Company's financial performance and could cause the Company's actual results for future periods to differ materially from

View Full Filing

View this 8-K filing on SEC EDGAR